Trial Profile
A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2019
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Selinexor (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Selvedex
- 07 Dec 2019 According to Karyopharm Therapeutics media release, data from this trial will be present at the American Society of Hematology (ASH) 2019 Annual Meeting taking place December 7-10, 2019 in Orlando.
- 07 Dec 2019 Results published in Karyopharm Therapeutics Inc Media Release
- 17 Jun 2018 Results (n=7) presented at the 23rd Congress of the European Haematology Association